Related by context. Frequent words. (Click for all words.) 71 cell lymphomas 66 follicular non 66 B CLL 64 hematological cancers 64 chronic lymphocytic leukemia CLL 63 castration resistant prostate cancer 62 tyrosine kinase inhibitors 62 humanized monoclonal antibody 61 lupus nephritis 61 lymphomas 61 leukemias 60 solid tumors 60 B lymphocytes 60 hepatocellular carcinoma HCC 60 cutaneous T cell 60 hematological malignancies 59 TREANDA 59 hematologic malignancies 59 selective inhibitor 59 PXD# 58 glioblastoma multiforme GBM 58 chronic myeloid leukemia CML 58 IMGN# 58 follicular lymphoma 58 FavId 58 autoimmune diseases 58 HGS ETR1 58 malignancies 57 blinatumomab 57 systemic lupus erythematosus 57 DLBCL 57 CYC# 57 CTCL 57 systemic lupus erythematosus SLE 57 PARP inhibitors 57 CLL 57 orally bioavailable 57 investigational compounds 57 androgen independent 57 BiTE antibody 57 chronic HCV 57 metastatic renal cell carcinoma 56 small molecule inhibitor 56 fusion proteins 56 MAb 56 kinase inhibitor 56 cell lymphoma 56 biologic therapy 56 immunomodulatory 56 immunotherapeutic 56 kinase inhibitors 56 HDAC inhibitor 56 cytomegalovirus CMV 56 subtype 56 hepatocellular carcinoma 56 resistant ovarian cancer 56 hematologic cancers 56 Marqibo 56 HCV infection 55 metastatic melanoma 55 chemotherapeutic agents 55 Perifosine 55 preclinical compounds 55 subtypes 55 bone metastasis 55 antitumor 55 Non Hodgkin lymphoma 55 hormone refractory prostate cancer 55 ofatumumab 55 TRIOLEX 55 Rituximab 55 AP# [003] 55 monoclonal 55 chronic HCV infection 55 HDAC inhibitors 55 metastatic colorectal cancer 55 small molecule inhibitors 55 aHUS 55 HspE7 55 BiovaxID 54 receptor agonist 54 relapsed multiple myeloma 54 recurrent ovarian cancer 54 oritavancin 54 refractory multiple myeloma 54 BAY #-# 54 induce apoptosis 54 anticancer agents 54 INGN 54 relapsing remitting multiple sclerosis 54 BCR ABL 54 radioimmunotherapy 54 interferon alfa 54 rituximab 54 renal cell carcinoma 54 glioblastoma 54 immune mediated 54 CTLA 4 54 TELCYTA 54 valopicitabine 54 daclizumab